Clinical research site network CenExel Clinical Research announced on Tuesday the appointment of Dr. Sy Pretorius as chief executive officer, effective 1 May 2026.
Dr. Pretorius succeeds Ryan Brooks, who will remain a member of the company's board of directors.
CenExel said that Dr. Pretorius joins the company with more than three decades of experience in clinical research leadership, spanning senior executive and management roles where he was instrumental in driving global clinical development programmes, early-phase research, and integrated clinical trial services.
Dr. Pretorius currently serves as CEO of Ergomed Group, where he leads value creation efforts across the PrimeVigilance, Ergomed CRO and ADAMAS businesses after the group transitioned from the public market to private equity ownership. Prior to joining Ergomed, he served as chief operating officer at EVERSANA, where he led drug and device commercialisation services. Earlier, as president of Clinical Development and chief medical officer at PAREXEL, he oversaw a USD3.6bn global P&L and led more than 16,000 employees worldwide.
Insmed reports Phase 2b study of brensocatib did not meet efficacy endpoints
Gilead to acquire Tubulis to expand ADC oncology capabilities
FDA grants Fast Track status to SIM0505 for platinum‑resistant ovarian cancer
Sanofi reports positive phase 2 results for lunsekimig in asthma and CRSwNP
Aelis Farma secures EUR458k France 2030 grant to advance metabolic disease programme
Immedica Pharma gains European approval to extend Efmody use in adrenal insufficiency
NeuroSense's PrimeC composition receives Brazilian patent
AstraZeneca reports positive Phase III data for Imfinzi and Imjudo in liver cancer
Thermo Fisher Scientific unveils CHOvantage GS Kit to speed biologics development
Frontier Medicines licenses FMC-220 oncology programme to LG Chem in global deal
NJ Bio and Aji Bio-Pharma partner to strengthen support for ADC development
Alltrna granted approval for first-in-human clinical trial of AP003
Lilly to acquire Centessa Pharmaceuticals for up to USD47 per share